Valuation: Summit Therapeutics Inc.

Market Cap 10.63B 14.07B 12.56B 11.69B 20.07B 1,361B 20.16B 141B 55.11B 694B 52.83B 51.67B 2,227B P/E 2026 *
-15.2x
P/E 2027 * -15.1x
Enterprise Value 10.16B 13.45B 12.01B 11.17B 19.18B 1,301B 19.27B 134B 52.68B 663B 50.49B 49.39B 2,129B EV / Sales 2026 *
3,462x
EV / Sales 2027 * 249x
Free-Float
19.11%
Yield 2026 *
-
Yield 2027 * -
09-22 Akeso, Inc. and Summit Therapeutics Inc. Showcase HARMONi-G11 Phase III Trial Data Featuring Ivonescimab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer At ESMO 2026 CI
09-15 Summit Therapeutics Presents Updated HarmonI Data At WCLC 2026 Demonstrating Consistent Overall Survival Results With Ivonescimab Plus Chemotherapy In Western And Asian Patients CI
09-14 Summit Therapeutics Shares Rise After Partner Akeso's Ivonescimab Phase 3 Lung Cancer Study in China Shows Survival Benefit MT
09-09 Summit Therapeutics Shares Rise After Upgrade From Jefferies MT
09-09 Jefferies Upgrades Summit Therapeutics to Buy From Hold, Adjusts Price Target to $25 From $15 MT
08-26 Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Amid Inflation Data Release MT
08-26 US Equity Futures Mostly Flat Pre-Bell as Traders Weigh Inflation Data, Await Nvidia Results MT
08-26 Summit Therapeutics Says Partner's Potential Biliary Tract Cancer Treatment Meets Primary, Secondary Endpoints MT
08-26 Summit Therapeutics Reports Positive Topline Results From Phase III HARMONi-GI1 Study Evaluating Ivonescimab Plus Chemotherapy Compared With Durvalumab Plus Chemotherapy In First-Line Advanced Biliary Tract Cancer CI
08-25 Wall Street Wants Receipts Zonebourse
08-25 Analyst recommendations: AMD, Dynatrace, Elastic, Revolution Medicines… Zonebourse
08-12 Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC MT
08-12 Leerink Partners Upgrades Summit Therapeutics to Market Perform From Underperform, Adjusts PT to $13 From $12 MT
1 day+2.45%
1 week+4.98%
Current month+4.02%
1 month+3.47%
3 months+15.34%
6 months-10.57%
Current year+0.57%
1 week 16.44
Extreme 16.44
18.33
1 month 15.18
Extreme 15.18
19.09
Current year 12.07
Extreme 12.07
29.23
1 year 12.07
Extreme 12.07
29.23
3 years 1.64
Extreme 1.64
36.91
5 years 0.66
Extreme 0.66
36.91
10 years 0.66
Extreme 0.66
36.91
Manager TitleAgeSince
Chief Executive Officer 55 25/07/2022
Chief Executive Officer 81 01/04/2020
Director of Finance/CFO 48 02/04/2024
Director TitleAgeSince
Chairman 81 01/02/2020
Director/Board Member 48 01/12/2019
Director/Board Member 55 11/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
6/4/26 A Buy

Chief Executive Officer

100,000 0.0129%
6/4/26 A Buy

Chief Executive Officer

100,000 0.0129%
6/4/26 A Buy

Chief Financial Officer

50,000 0.0064%
Change 5-day change 1-year change 3-year change Capi.($)
+2.45%+4.98%-17.61%+888.20% 14.07B
-2.59%-5.70%+39.83%+82.45% 70.61B
+3.23%-10.67%+6.27%+53.70% 51.01B
+1.56%+1.17%+8.49%+31.81% 48.1B
+0.39%+0.65%+31.14%+28.97% 42.78B
+0.87%-8.17%+293.37%+642.41% 40.67B
+1.24%-1.01%+10.74%+100.64% 40.3B
-2.13%-1.64%+8.63%+46.88% 30.59B
-0.46%-1.28%+42.23%+20.34% 28.16B
+5.32%+0.06%-5.00%-12.78% 24.36B
Average +0.99%-1.89%+41.81%+188.26% 39.06B
Weighted average by Cap. +0.63%-2.66%+46.90%+142.60%

Financials

2026 *2027 *
Net sales 2.94M 3.88M 3.47M 3.23M 5.54M 376M 5.57M 38.84M 15.22M 192M 14.58M 14.27M 615M 41.88M 55.42M 49.5M 46.05M 79.08M 5.36B 79.42M 554M 217M 2.73B 208M 204M 8.78B
Net income -701M -927M -828M -770M -1.32B -89.72B -1.33B -9.27B -3.63B -45.74B -3.48B -3.41B -147B -743M -983M -878M -817M -1.4B -95.16B -1.41B -9.83B -3.85B -48.51B -3.69B -3.61B -156B
Net Debt -470M -622M -555M -517M -887M -60.18B -891M -6.22B -2.44B -30.68B -2.34B -2.28B -98.46B -200M -265M -237M -220M -378M -25.63B -379M -2.65B -1.04B -13.07B -994M -973M -41.93B
Projected Income Statement - Annual - Summit Therapeutics Inc.
Logo Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Employees
265
Date Price Change Volume
09/10/26 $17.59 +2.45% 5,755,325
08/10/26 $17.17 -4.35% 6,179,332
07/10/26 $17.95 +3.70% 8,175,297
06/10/26 $17.31 +0.23% 5,875,829
05/10/26 $17.27 +3.07% 5,277,704
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Summit Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
13.29GBP
Average target price
22.51GBP
Spread / Average Target
+69.32%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Summit Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. SMMT Stock